Pancreatic Cancer
Pancreatic cancer bevacizumab treatment safe with chemoradiotherapy in phase I trial
Published in Cancer Weekly, April 24th, 2006
A group of oncologists in Texas conducted a study to evaluate "the safety of bevacizumab with capecitabine-based chemoradiotherapy."
"Patients with inoperable pancreatic adenocarcinoma received bevacizumab 2 weeks before radiotherapy (50.4 Gy treating the primary tumor and gross adenopathy), every 2 weeks during radiotherapy (12 patients each at 2.5, 5.0, 7.5, and 10 mg/kg), and after radiotherapy until disease progression," explained C.H. Crane and coauthors at the M.D. Anderson Cancer Center in Houston.
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2006-04-24)
More Articles from Cancer Weekly
- Astrocytomas
Gliomas graded using metabolite quantification with MR spectroscopic imaging - Colorectal Cancer
Colorectal cancer prognosis linked to indoleamine 2,3-dioxygenase expression - Lung Cancer
Lung cancer apoptosis enhanced by adenylate cyclase toxin - Ovarian Cancer
Ovarian cancer risk not linked to dietary fat, cholesterol and egg intakes - Prostate Cancer
Prostate cancer quality of life affected by spirituality - Abdominal Cancer
Habitual inclusion of pelvis on abdominal CT for abdominal tumors not justified - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
